1312479-26-7

Basic information

• Product Name: 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester
• Synonyms: 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester;4,4,5,5-tetramethyl-2-(4-(tetrahydro-2H-pyran-4-yl)phenyl)-1,3,2-dioxaborolane
• CAS NO: 1312479-26-7
• Molecular Formula: C₁₇H₂₅BO₃
• Molecular Weight: 306.20488
• Mol File: 1312479-26-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester(1312479-26-7)
• EPA Substance Registry System: 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester(1312479-26-7)

Safety Data

• Hazardous Substances Data: 1312479-26-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester is used as a synthetic building block for the development of new pharmaceutical compounds. Its unique structure allows for the creation of complex molecules with potential therapeutic applications, such as novel drugs for the treatment of various diseases.
Used in Materials Science:
In the field of materials science, 4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester is used as a key component in the synthesis of advanced materials with specific properties. These materials can be utilized in various applications, such as electronics, coatings, and adhesives, where their unique characteristics provide advantages over traditional materials.
Used in Chemical Research:
4-(4-Tetrahydropyranyl)phenylboronic Acid Pinacol Ester is also used as a research tool in the field of organic chemistry. Its reactivity and structural features make it an ideal candidate for studying various chemical reactions and mechanisms, contributing to the advancement of chemical knowledge and the development of new synthetic methods.

Upstream product

• 811828-76-9 4-(4-bromophenyl)-tetrahydro-2H-pyran 
• 73183-34-3 bis(pinacol)diborane 
• 62071-40-3 4-(tetrahydro-2H-pyran-4-yl)benzenamine 
• 73852-88-7 2-(4-iodophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 106-37-6 1.4-dibromobenzene 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 1613415-65-8 (R)-4-methyl-4-(4-(tetrahydro-2H-pyran-4-yl)phenyl)-1,2,3-oxathiazolidine 2,2-dioxide 
• 1312473-88-3 (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(tetrahydro-2H-pyran-4-yl)phenyl]pyridin-1(2H)-yl}butanamide 
• 1312479-27-8 (2R)-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(tetrahydro-2H-pyran-4-yl)phenyl]pyridin-1(2H)-yl}-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 

Relevant articles and documents

A Practical Method for Continuous Production of sp3-Rich Compounds from (Hetero)Aryl Halides and Redox-Active Esters

A practically useful coupling reaction between aromatic halides and redox-active esters was realized by nickel catalysis through the use of a packed zinc bed column in continuous flow. Multiple reuse of the column showed a negligible decrease in efficiency, affording high space/time yields. A wide range of substrates, including a number of heteroaryl halides and polyfunctional materials were coupled in generally good yields. Longer-time and larger-scale experiments further demonstrates the robustness of the system.

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen

WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells. We report the discovery and optimization of a 3,4,5-trisubstituted pyridine 9 using a high-throughput cell-based reporter assay of WNT pathway activity. We demonstrate a twisted conformation about the pyridine-piperidine bond of 9 by small-molecule X-ray crystallography. Medicinal chemistry optimization to maintain this twisted conformation, cognisant of physicochemical properties likely to maintain good cell permeability, led to 74 (CCT251545), a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. We demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing. This work provides a successful example of hypothesis-driven medicinal chemistry optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochemical target.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS

The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.

N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).